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tency was observed in the out-of-pocket questionnaire(p  0.05). Component analysis 
showed a few epidemiological variables are responsible for 80% of instrument’s vari-
ability. CONCLUSIONS: Validated resource-use questionnaires are needed to homog-
enize costs and EE in developing countries. These validated questionnaires in Mexican 
population could be used by authorities to enhance cost-containment policies.
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A QALY ALTERNATIVE FOR COST–EFFECTIVENESS ANALYSIS
IN HEALTH CARE
Gandjour A
Rice University, Houston, TX, USA
The cost-effectiveness of health care interventions is often evaluated using quality-
adjusted life years (QALYs) as a measure of outcome. However, QALYs are valid only
under several restrictive assumptions. Furthermore, QALYs are ethically controversial,
as they receive their strongest support from utilitarian theory, which is often consid-
ered an unacceptable ethical theory. The purpose of this work is to present a non-
utilitarian approach to cost-effectiveness analysis, which avoids calculating QALYs, 
but still is able to aggregate and compare different clinical outcomes. By capturing 
beneﬁ ts in terms of adverse events (AEs) avoided, the approach is based on one of the 
fundamental metrics of clinical epidemiology and thus moves the assessment of cost-
effectiveness closer to that of clinical outcomes in clinical trials. Furthermore, it 
directly incorporates the two most important ethical values with regard to setting 
priorities in health care, ie, a concern for health gain as well as for health without
treatment. The approach aggregates the different types of AEs avoided, by introducing
weights that reﬂ ect their value. In order to project weights on an interval scale, ranking
data, the time trade-off, or the standard gamble method can be used.
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DETERMINING COSTS OF CONCOMITANT MEDICATIONS
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OBJECTIVES: Determining costs of concomitant medications (CONMEDs) is a chal-
lenging but critical component of cost-effectiveness analysis. In clinical trials,
CONMEDs are typically recorded using broad medication terms, with approximate 
costs linked to the entire category. In a recent phase III oncology clinical trial, we 
determined costs with an alternative approach based on the individual CONMEDs 
used by patients, using a combination of WHO preferred medication term codings, the 
NDC-HCPCS Crosswalk (CW), and Payment Allowance Limits (PAL) for Medicare
Drugs Part. METHODS: The CONMED database was obtained from the clinical trial, 
and the CW and the PAL were obtained from CMS. Preferred medication terms of 
individual CONMEDs were coded according to the WHODrug version 2003 Q2 dic-
tionary. The CW was used to map preferred medication terms to appropriate HCPCS
codes, and the PAL was used to determine unit costs of the HCPCS coded medications. 
For medications with multiple HCPCs codes, the average payment limit per dosage unit
was assigned. Total CONMED costs were computed by adding all cost information. 
RESULTS: The CONMED database comprised approximately 400 patients and 3,588
CONMED records. There were 562 unique HCPCS codes and 497 unique preferred
medication terms in the CW and the PAL. In addition, there were 519 unique combina-
tions of preferred medication terms and dose units, of which 78% (407/519) had mul-
tiple NDC codes. However, only 17% (70/407) of these had different unit payment
limits across products within the combination. In these cases the average cost was used. 
Overall we were able to assign costs to 22% (780/3588) of CONMED records, consis-
tent with the proportion of CONMEDs covered by Medicare. CONCLUSIONS: From 
third party payer perspective, this micro-costing method for CONMEDs was a feasible 
approach to pharmacoeconomic assessment with a clinical trial.
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OBJECTIVES: To evaluate an online freeware, cost-effectiveness calculator that gener-
ates and plots estimations related to the impact of medication compliance on life years
gained, drug expenditures, and total health care cost. METHODS: An online calcula-
tor and plotter were developed that estimates the impact of patient compliance on the 
cost-effectiveness of therapy. This model was based on a more complex compliance 
model description published by Hughes D. et al. The online data calculations were
compared with an MS Excel spreadsheet model. The cost effectiveness calculator is 
freely available through www.healthstrategy.com. Data inputs that can be modiﬁ ed 
include (for compliant and non-compliant separately): utility (QoL), annual drug
costs, annual non-drug costs, percent deaths per year, total number of study years, 
and number of initial patients. RESULTS: The online calculator runs on most personal
computer operating systems with javascript enabled browsers such as Internet
Explorer, Firefox, Opera, or Safari. For twenty different levels compliance (from 0 to
100 percent) this Internet tool outputs and plots results for: total QALYs, life years, 
total health care costs, non-drug expenditures and total health care expenditures. For 
100 patients over 5 years, the MS Excel spreadsheet data versus the online calculated 
values compared as follows for 50% compliance: QALYs (372 vs. 375), Life Years:(451
vs. 450), drug costs:($23,750 vs. $23,750), non-drug costs:($228,750 vs. $225,000), 
total health care costs:($252,500 vs. $248,750). CONCLUSIONS: With this online 
compliance and cost-effectiveness software, the user can enter their own data to cal-
culate and graph estimated QALYs, Life Years, drug costs, non-drug costs and total
health expenditures. This web-based calculator has potential beneﬁ t as a basic tool 
for students, health professionals, and decision-makers.
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OBJECTIVES: To evaluate an online, freeware calculator that generates and plots
sample size estimations and power analyses for cost effectiveness studies. METHODS:
Online software was developed and results were compared with a published analytical 
formula for power analysis and sample size calculations for cost and effectiveness data. 
The web-based, cost effectiveness calculator formulas, data and evaluation were based
on published articles by Briggs A, Gray AM and Tambour M. The online calculator 
required data inputs include: probability of Type I and Type II error, standard devia-
tion of costs and effects, mean cost and effect differences, correlation between differ-
ences in cost and effects, as well as willingness to pay (WTP) for additional health
effects. This Internet tool outputs results for sample size in each study arm that would
be required versus WTP threshold ranges, and power versus sample size. RESULTS:
Compared to the published manuscripts for a power of 0.90 and effectiveness only, 
the online calculated sample size results were identical (N  536). For the published 
examples with correlation differences in effect and cost of minus 1.0, the estimated 
sample sizes based on WTP compared as follows: WTP  $7500:(1400 vs 1387), WTP 
 $10,000:(1150 vs 1096), WTP  $15,000:(850 vs 865), WTP  $20,000:(790 vs 
769), WTP  $30,000:(700 vs 682). The Briggs et al articles include additional results
and sensitivity analyses based on additional correlations and power, which have to be
run one at a time with the online software. CONCLUSIONS: With this online freeware 
calculator, the user can enter their own data to estimate sample size and power in
planned or published cost effectiveness studies. This web-based software has potential
beneﬁ t as a basic tool for students, health professionals, and decision makers.
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OBJECTIVES: A major concern about the economic impact of preventive care
and medicines is that savings from avoiding morbidity may be more than offset 
by the costs of prolonging life, resulting in a net expenditure increase. The purpose
of this work is to examine this hypothesis. METHODS: A theoretical model is 
developed which determines the net outcome when savings from preventing morbidity 
are weighed against expenditures for added life years. The model is based on a single 
assumption, which is that costs and mortality are linearly correlated. This assumption 
holds for preventing the average disease because preventing all disease reduces 
mortality and costs by 100%. The model is validated based on long-term studies 
from the U.S. and Netherlands that model the economic impact of chronic-disease 
prevention. RESULTS: The model shows that for the average preventive measure 
savings from preventing morbidity are somewhat larger than expenditures in added 
life years. The ratio of savings to expenditures is approximately 1/(1 – relative reduc-
tion in all-cause mortality). The model is able to explain why some studies show 
that preventing chronic disease leads to savings while others do not. CONCLUSIONS:
This work provides new insight into the cost consequences of preventive care and
medicines. Results have implications for the economic evaluation of preventive 
medicines. For the average drug the long-term cost driver is not the additional life 
span, as expenditures during added life years roughly equal savings from morbidity 
reduction. Instead, increases in long-term costs are, on average, mainly driven by the 
medication itself.
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OBJECTIVES: To estimate the treatment effects of biologic disease modifying anti-
rheumatoid drugs (DMARDs) on quarterly total health care expenditure, while 
controlling endogeneity in treatment choice and allowing heterogeneity in treatment 
effects. The structural parameters, heterogeneous (ATE), and homogeneous (ATE1) 
average treatment effects were deﬁ ned as the impact of treatment on quarterly 
expenditure, if patients are randomly assigned to biologic DMARDs. METHODS:
Retrospective cohorts were constructed from California Medicaid paid claims between
January 1, 1999 to December 31, 2005. Non-overlapping quarters were created from 
pharmacy claims for biologic (adalimumab and etanercept) and standard (leﬂ uono-
mide, hydroxychloroquine and sulfasalazine) DMARDs. Final sample included 24504
episodes on 5510 patients. In the two-stage estimation, the treatment selection 
model was varied between multinomial and nested-logit, to avoid independence of 
irrelevant alternatives. The outcome equation was panel data ﬁ xed-effects correlated
random coefﬁ cients model (Wooldridge-2005), allowing heterogeneity in parameters.
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Endogeneity was controlled by addition of a generalized residual function, constructed
using Lee’s (1983) approach for non-normal polychotomous choice models. Hypoth-
esis testing was based on cluster-bootstrapped errors. RESULTS: Controlling endoge-
neity signiﬁ cantly increased ATE1 for adalimumab, while decreasing ATE1 for
etanercept, compared to naïve ﬁ xed-effects model. ATE1 estimate from the nested-logit 
selection model based correction was lower as compared to multinomial-logit. When 
heterogeneity in parameters was allowed, ATE of adalimumab was no longer statisti-
cally signiﬁ cant under the nested-logit corrected model (ATE  $160,108, p  0.43).
ATE for etanercept ($17,466, p  0.93) was no longer statistically signiﬁ cant under
either of the endogeneity corrected models. Based on likelihood-ratio test for the
selection model, and t-test for time-varying endogeneity, the appropriate model was 
the nested-logit based endogeneity corrected ﬁ xed-effects model. CONCLUSIONS:
Random assignment of patients currently on standard DMARD treatment to either
adalimumab or etanercept may not cause a signiﬁ cant difference in quarterly expen-
diture, if treatment effects are heterogeneous and treatment decision are based on these 
individual gains.
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OBJECTIVES: To estimate the impact of varying selection bias correction techniques
on the average treatment effect. The structural parameters, heterogeneous (ATE), 
and homogenous (ATE1) average treatment effects were deﬁ ned as the impact of 
treatment on total quarterly expenditure, if patients are randomly assigned to biologic 
disease modifying anti-rheumatoid drugs (DMARDs). METHODS: Retrospective
cohorts were constructed from California Medicaid paid claims from January 1, 1999 
to December 31, 2005. Non-overlapping quarters were created from pharmacy
claims for biologic (adalimumab and etanercept) and standard (leﬂ uonomide, 
hydroxychloroquine and sulfasalazine) DMARDs. Final sample included 24,504 epi-
sodes on 5,510 patients. In the two-stage estimation, the treatment selection model 
was estimated by multinomial-logit. The outcome model was ﬁ xed-effects correlated 
random coefﬁ cients model (Wooldridge-2005), allowing parameter heterogeneity. A 
generalized residual function constructed based on four different bias-correction tech-
niques for the multinomial-logit selection model namely, Lee’s (1983) (LEE), Dubin
and MacFadden’s (1984) (DMF) and two variants of Dahl’s (2002) approach (squared
(DHL1) and quadratic (DHL2) series expansions without interactions); controlled 
endogeneity in treatment choice. The generalized residual was regressed on exogenous
covariates to assess multicollinearity. Hypothesis testing was based on cluster-boot-
strapped errors. RESULTS: Multicollinearity was not an issue for LEE (RSQUARE 
0.07) and DMF (RSQUARE  0.08) approaches, however, it was strong in DHL1 
(RSQUARE  0.48) and DHL2 (RSQUARE  0.62), even with six exclusion restric-
tions. Time-varying endogeneity was signiﬁ cant under all approaches. Controlling
endogeneity signiﬁ cantly increased ATE1 for adalimumab, in LEE and DMF 
approaches but decreased in magnitude in DHL1 and DHL2 as compared to naïve
ﬁ xed-effects model. When heterogeneity in parameters was allowed, ATE of adalim-
umab was signiﬁ cantly higher as compared to standard DMARDs, under all bias-
correction techniques. ATE for etanercept under LEE ($46,187, p  0.75) and DMF 
($76,393, p  0.59) was not signiﬁ cant. However, ATE for etanercept under DHL1 
($192,813, p  0.001) and DHL2 ($191,463, p  0.013) was signiﬁ cantly higher as 
compared to standard DMARDs.
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OBJECTIVES: To compare two methods of constructing control cohorts for a differ-
ence-in-difference (DID) econometric model in evaluating the impact on cost-saving 
after implementing an intervention intended to reduce variation in inpatient care for 
patients with community acquired pneumonia (CAP). METHODS: Using data from 
Ofﬁ ce of Statewide Health Planning and Development (2000 to 2006), inpatient dis-
charge records from four southern California licensed hospitals implementing the
intervention were used to identify a CAP cohort. Controls were identiﬁ ed from other
California county hospitals using two methods: 1) criteria-matching, which matched 
on hospital similarity using three criteria: total number of discharges per year, number 
of California Medicaid patients, and race; and 2) propensity score (PS) matching, 
which matched on patient baseline demographic and clinical characteristics. A DID
econometric model was applied to determine intervention impact on inpatient length
of stay (LOS). A zero-truncated negative binomial regression model was performed to 
capture the change in total LOS. The model was repeated for both criteria-matched 
and PS matched cohorts. Proxy cost per inpatient day ($2,127) was multiplied by 
the change in LOS to calculate total cost savings. RESULTS: For criteria-matched
(N  36,018), mean LOS decreased for both case (0.22 days) and controls (0.10 days)
following intervention implementation. DID results showed a decrease of 0.94 days 
per case, corresponding to $440 savings per case per year (p  0.02). Results for the 
PS-matched cohorts (N  22,570) also indicated a decrease in mean LOS for case (0.23 
days) and controls (0.18 days) following implementation. However, DID results 
revealed that these differences in LOS change were not signiﬁ cant (p  0.83). CON-
CLUSIONS: The use of different methods for constructing control cohorts in the DID
analysis signiﬁ cantly impacted the evaluation of intervention effectiveness. A PS-
matched method allowed us to control observable patient characteristics and conduct 
a more appropriate evaluation.
PMC23
WHERE IS THE CURRENT FOCUS OF HEALTH ECONOMICS? AN
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OBJECTIVES: Health economics is evolving as a sub-discipline that comprises several 
key areas: (A) inﬂ uences on health other than health care, (B) what is health and its
value, (C) demand for health care, (D) supply of health care, (E) microeconomic 
evaluation, (F) market equilibrium, (G) whole-system evaluation, and (H) planning, 
budgeting, and monitoring systems, deﬁ ned in a key article by Maynard and Kanavos
(Health Economics, 9:183–190, 2000). This research evaluates the proportion of lit-
erature published within these areas across three key health economics journals. 
METHODS: All articles published in Value in Health (ViH), Health Economics (HE), 
and Journal of Health Economics (JoHE) during the year 2008 were categorised by
area and author nationality (US or non-US) based on the abstract. The number of 
publications per area was calculated and the relative proportions computed as a per-
centage. RESULTS: Within ViH the majority of the published work relates to micro-
economic evaluation (26%) or the value of health (25%), particularly quality of life
and utility development/validation. In contrast, JoHE focuses on the deﬁ nition of 
health (23%) and planning, budgeting, and monitoring activities (22%), particularly
in respect to the inﬂ uence on health of policy introduction and government regulation. 
Although the focus of HE appears to be more dispersed, a large share of the literature 
again relates to monitoring health outcomes following changes in government policy/
regulation (19%). Overall, in 2008 microeconomic evaluation attracted the most 
interest (18%) whilst whole-system evaluation and market equilibrium attracted the 
least (7% and 5%, respectively). CONCLUSIONS: The central focus of the literature 
within each of the key health economics journals differs. However, both microeco-
nomic evaluation and assessment of the effect of policies/regulations on health appears 
of major interest in general. Whole-system level evaluation has received comparatively 
little attention; such analysis could be considered important in when making health 
care-related policy decisions.
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OBJECTIVES: To identify and characterize patients with hormone resistant prostate 
cancer (HRPC) in a managed care setting using diagnosis and serial PSA test result
and a statistical algorithm. METHODS: Patients with hormone-treated prostate 
cancer were identiﬁ ed from the Ingenix database of 42 million covered lives, 
07/01/2001–12/31/2007. Patients with available PSA data were stratiﬁ ed into two
groups based on their PSA results: known HRPC  1 or not known HRPC  0. A
prediction model using logistic regression to model known HRPC status as a function
of baseline clinical, demographic, utilization and expenditure measures identiﬁ able in 
claims data was utilized. The parameter estimates from the logistic model were then
applied to the entire hormone-treated population, including those without PSA data,
and predicted values (propensity scores) were obtained for all subjects. A threshold 
propensity score value for HRPC cases using sensitivity and speciﬁ city measures was 
established. RESULTS: A total of 15,353 patients with hormone treated prostate
cancer were identiﬁ ed during the study period. Based on PSA results 349 of those were
known HRPC and 625 patients were not HRPC. The remaining 14,379 patients did 
not have sufﬁ cient PSA data and were classiﬁ ed as unknown HRPC status. With the
prediction model, an additional 2,350 patients were classiﬁ ed as meeting the threshold 
propensity score value of 0.32 (sensitivity  0.76, speciﬁ city  0.73) in addition to the 
349 true cases totaling 2,699 HRPC patients. The demographic, clinical, utilization
and expenditure characteristics of the known HRPC sample and those identiﬁ ed using 
the prediction model were highly comparable. CONCLUSIONS: In the absence of 
PSA test results, a prediction model utilizing other claims-based measures may be used 
to identify possible HRPC patients.
